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Background. TNF-𝛼 inhibitors have shown to be effective in reducing disease activity and improving the quality of life. Due to
the high costs associated with acquisition of this treatment, this study was undertaken to evaluate the ICER of TNF-𝛼 antagonists
(etanercept, adalimumab, and infliximab) in improving the quality of life.Methods.TheHAQand SF-36were administered at phases
1, 2, and 3, in order to assess the improvement in the QOL. Suppression of disease activity was assessed through the DAS-28.Results.
Statistically significant improvements (𝑃 < 0.05) were noted for the SF-36 and HAQ after 3 months and for the DAS-28 after 6
months of TNF-𝛼 inhibitor therapy.Themean ICER per 10% improvement in theHAQ,DAS-28, and SF-6Dwere C1976.5, C2086.5,
and C2316.4, respectively, following 6 months of TNF-𝛼 intervention. Most favorable ICERs were reported from a patient who had
to undergo surgical intervention whilst on DMARD therapy.Conclusion. Significant improvement was observed in patients’ quality
of life, after a short timeframe of 6 months. Such data is useful information in the light of convincing policy makers, in terms of
providing access to the medications to individual patients on national health service schemes.
1. Introduction
Rheumatoid arthritis (RA) is a progressive, inflammatory
disease which is characterised by inflammation of the joint
synovium that could ultimately progress to joint destruction
[1, 2]. Due to its chronic, immune-mediated course, long-
term treatment with immune-modulatory drugs is generally
required [3]. This disabling condition, is thought to affect
0.3–1.2% of the worldwide population [4]. Uncontrolled RA
results in progressive joint destruction and functional decline
[5]. This disabling condition imposes substantial economic
burden through the decreased quality of life (QOL) and loss
of productivity [6].
Recent advances in biotechnology and pathogenesis of
RA have led to the discovery of biological DMARDs [6].
Biological agents inhibit pro-inflammatory cytokines which
are believed to have a crucial role in the inflammatory process
within the synovial joint [7]. TNF-𝛼 inhibitors have proved
their clinical efficacy and raised the previous goals of RA
treatment [5, 8]. Clinicians nowadays aim to achieve low dis-
ease activity or preferably remission and not merely slowing
the progression of the disease and controlling symptoms [9].
The discovery of biological agents has led to a drastic shift in
the therapeutic approach to RA, leading to a better QOL [10].
Yet, these breakthrough drugs are associated with high
procurement costs. This ultimately increases the financial
burden RA imposes on society [4, 5]. Such a scenario has
elicited the need to carry out pharmacoeconomical assess-
ments in order to inform policy and decision makers of the
cost-effectiveness of the biological DMARDs [5, 8]. Hence,
this study was undertaken to determine the improved QOL
and the incremental cost-effectiveness ratio (ICER) involved
in treating Maltese patients suffering from resistant RA, with
TNF-𝛼 inhibitors.
2. Materials and Methods
Data collection used to conduct this 6-month study was
carried out at the Rheumatology Outpatient Clinic at Mater
Dei Hospital. Patients were eligible to participate in the study
provided that they had been diagnosed with RA according
to the 1987 ACR classification criteria, failed to achieve a
low disease activity despite DMARD/s therapy; and were
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switched onto a TNF-𝛼 inhibitor (etanercept, adalimumab
or infliximab). Patients were not eligible to participate if
pregnant or planning to conceive suffering from TB or hep B;
they are diagnosed with juvenile chronic arthritis, ankylosing
spondylitis, osteoarthritis, psoriatic arthritis, and/or any
other rheumatological condition.
Following approval from the Maltese Research Ethics
Committee Board, patients identified for participation were
briefed on the purpose of the study. A signed consent form
was obtained from every patient who accepted to participate,
out of their own voluntarily will.
The disease-specific Health Assessment Questionnaire
(HAQ) was chosen as an outcome measure tool to assist in
the evaluation of the functional improvement experienced
by patients that were switched onto TNF-𝛼 inhibitor therapy.
The HAQ is a reliable tool used by various studies to assess
daily activities, namely, dressing, grooming, eating, walking,
hygiene, and so forth. Each of these items is given a score from
0 (without any difficulty) to 3 (unable to perform) reflecting
the patient’s ability in performing a particular activity [11].
The generic SF-36 is a health status questionnaire which
has become a predominant tool in assessing various medical
interventions consisting of 8 domains and 2 summary scores
[12]. Unlike theHAQ, the higher the score obtained in each of
the SF-36 domains, themore it indicates a better health status
in the respective domain.
The DAS-28 was used as a clinical outcome measure
tool in order to monitor disease activity with biological
intervention. The DAS-28 generates a continuous scale (0 to
9.4) through the assessment of tender joints (0–28), swollen
joints (0–28), erythrocyte sedimentation rate (mm/hr), and
the Visual Analogue Scale (0–100) [13].
This prospective study, carried out between 2010 and
2011, had a time phase of 6 months, during which patients
were assessed 3 times through the SF-36 and HAQ. At
phase 1 (t—0 months), patients were still being treated with
conventional DMARD therapy. Failure to achieve the desired
outcome and following discussions with the rheumatology
consultant, patients were identified as suitable candidates
for initiation of TNF-𝛼 inhibitor therapy. Subjects who
accepted to participate in the study were interviewed by the
investigator using the HAQ and SF-36. Raw data obtained for
both the SF-36 and the HAQ were inputted in a Microsoft
Excel Database.The final HAQ score and summary scores for
every SF-36 domain were calculated. At phase 2 (t—3months
after initiation of TNF-𝛼 inhibitor therapy), participants were
reinterviewed using the same questionnaires. At phase 3 (t—6
months), data from the SF-36 and HAQ were again collected
following 6 months of TNF-𝛼 inhibitor therapy.
The SF-36 scores were converted into SF-6D scores using
the algorithms provided by the University of Sheffield. The
Excel program based on nonparametric Bayesian preference
weights was chosen since the non-parametric model has
shown added benefits in the predictive capacity of the model
over the parametric random effects model [14]. The raw
scores for every item within the SF-36 for all the 13 patients
were inputted in the Excel programme which generated
utility values, anchored at 0 for dead and 1 indicative of full
health [15].
During both phases 1 and 3, patients were examined by
the rheumatology consultant and assigned a DAS-28 score as
a measure of disease activity. In both phases, medical case
notes of patients were reviewed and related data were col-
lected, namely, DAS-28 scores, treatment regimens, adverse
events, history of hospitalisation during the study period, and
surgeries performed related to RA.
Data collected from the HAQ and SF-36 questionnaires
were analyzed statistically using SPSS version 18.0. The one-
way ANOVA test was used to compare the mean scores
obtained during phase 1, 2, and 3 for both the HAQ and
the SF-36. Scores obtained in the HAQ and SF-36 were
also analysed using the post hoc Tukey’s test where pairwise
comparison between the mean rating scores of any two visits
was carried out.
The costs of TNF-𝛼 inhibitors, DMARDs, and glucocor-
ticoids involved in the study were obtained from the Maltese
Government Health Pharmaceutical Services (GHPS). Treat-
ment regimens for every patient were obtained by scrutiny of
patients’ notes prior to initiation of TNF-𝛼 inhibitor therapy
(Treatment B) and after 6 months of biological therapy
(Treatment A). Costs of Treatment B included the costs of
DMARDs and concomitant steroids for a period of 6 months
prior to phase 1. Hospitalization and hip replacement surgery
costs were included, assuming that the use of a TNF-inhibitor
would have decreased the need of hospitalization and hip
replacement surgery. Currently, Maltese patients, who have
an inadequate response tomultipleDMARDs and suffer from
moderate to severe RA, are considered for biological agent
therapy as recommended by the ACR guidelines [8]. Prior to
commencement of a TNF-𝛼 inhibitor, patients participating
in the study had been on the same nonbiological DMARD/s
for at least 6months.Thedirect costs of TreatmentA included
the cost of the biological agent being administered, any
concomitant DMARD, and steroids for a period of 6 months.
The economic evaluation used in this study was a cost
effectiveness analysis (CEA) which combines the difference
between the costs of treatments with improvement achieved
through biological intervention. The difference in costs
between treatments was established by subtracting the cost
of Treatment B from Treatment A for every patient. The
improvement in the HAQ was chosen as a unit of health
benefit since the HAQ is a strong predictor of the functional
disability observed in patients with RA through loss of
productivity [5, 16]. The ICER per unit of improvement in
HAQ was calculated using the following formula:
ICER per unit improvement in HAQ
= (Cost of Treatment A − Cost of Treatment B)
× (HAQ score on Treatment B
−HAQ score on Treatment A)−1.
(1)
The DAS-28 score was also used as a unit of health benefit,
as it highly reflects the disease activity and is thus useful in
indicating the suppression of disease activity following a ther-
apeutic intervention [13]. The ICER per unit of improvement
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in the DAS-28 through biological intervention was calculated
using the following formula:
ICER per unit improvement in DAS-28
= (Cost of Treatment A − Cost of Treatment B)
× (DAS-28 score on Treatment B
−DAS-28 score on Treatment A)−1.
(2)
Both theHAQand theDAS-28 give an ordinal scoring system
which is often criticized if used as a unit of health benefit to
express the incremental ICER [4].The SF-6D provides scores
on a cardinal scale from 0 to 1 with equal grades and can
therefore be used in assessing cost effectiveness of a health
intervention [17].
Hence, the ICER was expressed in terms of unit improve-
ment in the SF-6D using the following formula:
ICER per unit improvement in SF-6D
= (Cost of Treatment A − Cost of Treatment B)
× (SF-6D utility index on Treatment B
− SF-6D utility index Treatment A)−1.
(3)
Comparison between resulting ICERs using the 3 different
methodologies could not be made since the (i) HAQ gave
scores ranging from 0 to 3, (ii) the DAS-28 scores ranged
from 0 to 9.4, and (iii) the SF-6D ranged from 0 to 1. This has
prompted the researcher to devise a scoring scheme ranging
from 0 to 10 in order to compare ICERs obtained over a
6-month period. The resulting ICERs from all 3 different
methodologies were calculated and expressed in terms of this
scoring scheme. One-way Anova testing was conducted on
the resulting ICERs in order to assess significance between
outcome health benefits chosen.
3. Results
13 patients were recruited within the study out of which 85%
were females, with a mean age of 54 years. Patients had been
suffering from RA, prior to initiation of TNF-𝛼 inhibitor
therapy for a mean of 11 years ranging from 4 to 31 years.
As shown in Figure 1, the mean HAQ scores achieved in
phase 1 were the highest indicating the functional disability
experienced despite conventional DMARD therapy. Substan-
tial improvement was noted after 3 months of biological
therapy. Progress achieved was sustained and continued to
improve during the last 3 months of the study, yet to a lesser
extent than in the previous 3 months.
Table 1 shows that all activities assessed within the HAQ
have improved significantly (𝑃 < 0.05) between phase 1 and
2. The mean difference in the HAQ scores obtained between
phase 2 and phase 3 was not statistically significant (𝑃 >
0.05). During the whole study, themean scores obtained were
statistically significant (𝑃 < 0.05). This result indicates that
significant improvement is observed as early as 3months after
initiation of TNF-𝛼 inhibitor therapy.
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Figure 1: Illustration of the HAQ scores reported by patients at
baseline, at 3 months, and 6 months following TNF-𝛼 inhibitor
therapy.
Table 1: Analysis of HAQ scores.
Daily activities (HAQ) Phase Differencein mean P values
∗
Dressing and grooming
Phase 1-Phase 2 0.96 0.00
Phase 1-Phase 3 1.00 0.00
Phase 2-Phase 3 0.04 0.98
Rising
Phase 1-Phase 2 1.08 0.00
Phase 1-Phase 3 1.23 0.00
Phase 2-Phase 3 0.15 0.62
Eating
Phase 1-Phase 2 1.18 0.00
Phase 1-Phase 3 1.26 0.00
Phase 2-Phase 3 0.08 0.91
Walking
Phase 1-Phase 2 1.12 0.00
Phase 1-Phase 3 1.27 0.00
Phase 2-Phase 3 0.15 0.75
Hygiene
Phase 1-Phase 2 0.97 0.00
Phase 1-Phase 3 1.03 0.00
Phase 2-Phase 3 0.05 0.97
Reach
Phase 1-Phase 2 0.96 0.00
Phase 1-Phase 3 1.12 0.00
Phase 2-Phase 3 0.15 0.83
Grip
Phase 1-Phase 2 1.10 0.00
Phase 1-Phase 3 1.23 0.00
Phase 2-Phase 3 0.13 0.80
Activities
Phase 1-Phase 2 1.44 0.00
Phase 1-Phase 3 1.46 0.00
Phase 2-Phase 3 0.03 0.98
The difference in mean scores obtained between phases for every activity
assessed within the HAQ and their relative level of significance (significance
noted at 𝑃 < 0.05∗).
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Figure 2: Illustration of theDAS-28 scores reported by every patient
at baseline (prior to initiation of TNF-𝛼 inhibitor therapy) and at
phase 3 (6 months after initiation of TNF-𝛼 inhibitor therapy).
Table 1 shows the difference in mean scores obtained
between phases for every activity assessed within the HAQ
and their relative level of significance (significance noted at
𝑃 < 0.05
∗).
As noted from Figure 3, patients reported low functional
status in the SF-36 whilst on DMARD therapy. During
phase 2 and 3, all patients reported an improvement in the
functionality for all domains within the SF-36. The greatest
improvement was observed in the physical and emotional
role between phase 1 and 2. The least improvement reported
was for general health.
Every SF-36 domain improved significantly between
phase 1 (baseline) and phase 2 since 𝑃 values obtained were
<0.05 level of significance (Table 2). As observed with the
HAQ scores, 𝑃 values between phase 2 and 3 for every
SF-36 domain were not significant (𝑃 > 0.05). SF-36
domains improved significantly after 6 months of biological
intervention between phase 1 and 3 (𝑃 < 0.05). Lower 𝑃
values were obtained for the ER and BP when compared with
other domains between phase 2 and 3, thereby indicating
continuous improvement during the latter part of the study.
Table 2 shows the difference in mean scores obtained
between phases for every SF-36 domain and their relative
level of significance (significance noted at 𝑃 < 0.05∗).
During phase 1, as observed in Figure 2, 85% of patients
(𝑛 = 11) scored higher than 5.1 indicating a high disease
activity according to the EULAR criteria. In accordance with
the EULAR criteria response, a decrease of 1.2 from the initial
DAS-28 score has been found to indicate a significant change
and is thus considered as a good response [13]. After 6months
of biological intervention, theDAS-28 decreased significantly
(>1.2) for all 13 patients. 31% of patients (𝑛 = 4) scored <3.2 in
the DAS-28 which corresponds to low disease activity whilst
15.4% (𝑛 = 2) scored <2.6 which is compatible with disease
Table 2: Analysis of SF-36 scores.
SF-36 domain Phase Differencein mean (%) P value
∗
Physical function (PF)
Phase 1-Phase 2 36.54 0.00
Phase 1-Phase 3 38.46 0.00
Phase 2-Phase 3 1.92 0.96
Physical role (PR)
Phase 1-Phase 2 69.23 0.00
Phase 1-Phase 3 73.08 0.00
Phase 2-Phase 3 3.85 0.94
Emotional role (ER)
Phase 1-Phase 2 64.07 0.00
Phase 1-Phase 3 79.46 0.00
Phase 2-Phase 3 15.40 0.20
Bodily pain (BP)
Phase 1-Phase 2 51.62 0.00
Phase 1-Phase 3 58.62 0.00
Phase 2-Phase 3 7.00 0.48
Vitality (V)
Phase 1-Phase 2 41.92 0.00
Phase 1-Phase 3 44.23 0.00
Phase 2-Phase 3 2.31 0.85
Social functioning (SF)
Phase 1-Phase 2 54.81 0.00
Phase 1-Phase 3 56.73 0.00
Phase 2-Phase 3 1.92 0.93
Mental health (MH)
Phase 1-Phase 2 32.62 0.00
Phase 1-Phase 3 34.15 0.00
Phase 2-Phase 3 1.54 0.97
General health (GH)
Phase 1-Phase 2 25.08 0.00
Phase 1-Phase 3 26.85 0.00
Phase 2-Phase 3 1.77 0.90
The difference in mean scores obtained between phases for every SF-36
domain and their relative level of significance (significance noted at 𝑃 <
0.05
∗).
remission. 54% of patients (𝑛 = 7) scored values compatible
with moderate disease activity (>3.2 ≤5.1) [13].
A slight improvement in theHAQ score despite biological
intervention results in a high ICER (Table 3). Patient 10
experienced a minimal improvement in the quality of life
which gave an ICER of C26,030 over a period of 6 months.
The rest of subjects (𝑛 = 12) experienced a much lower ICER
due to a higher improvement recorded in the quality of life.
Patient 13 had undergone a hip replacement surgery prior
to phase 1 and hence gave a more favorable ICER, due to a
lower discrepancy between the costs of treatments. In order
to improve by 10% in the quality of life as measured by the
HAQ, an average addition of C1,977 is incurred over a period
of 6 months.
Table 3 shows the ICERs per unit improvement and per
10% improvement in the HAQ following 6 months of TNF-𝛼
inhibitor therapy.
The least reduction in disease activity was again reported
by patient 10 (Table 4).This eventually resulted in the highest
ICER per unit of improvement in the DAS-28. The lowest
resulting ICER was incurred again by patient 13. For every
unit of improvement in the DAS-28 (reduction in disease
International Journal of Inflammation 5
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Figure 3: Illustration of the scores for every domain within the SF-
36 at baseline, at 3 months, and 6months following TNF-𝛼 inhibitor
therapy.
activity by 1 on a scale from0 to 9.4) an increase of C2,200was
incurred over a period of 6 months.The average reduction in
disease activity (DAS-28) was of 2.71, which is considered as
a significant good response (>1.2) [13]. In order to achieve a
reduction of 10% in theDAS-28 score (i.e., 0.94), it would cost
the Maltese Government an additional C2,087.
Table 4 shows the ICERs per unit improvement and per
10% improvement in theDAS-28 following 6months of TNF-
𝛼 inhibitor therapy.
An average patient, following 6 months of TNF-𝛼
inhibitor, gained a 0.27 improvement in the utility health
index, the SF-6D. Theoretically, an ICER of C 23,164 is
incurred for a patient to regain a perfect quality of life (1) from
a state (0) equivalent to death (Table 5). An improvement of
0.1 as assessed through the SF-6D would cost the payer an
additional C2,316.
Table 5 shows the ICERs per unit improvement and per
10% improvement in the SF-6D following 6 months of TNF-
𝛼 inhibitor therapy.
No significant difference (𝑃 > 0.05) was noted between
the 3 different methodologies used to calculate the ICER
(Table 6). The choice of the SF-6D yielded the higher ICER
when compared to resulting ICERs in terms of the HAQ and
DAS-28.
Table 6 shows the level of significance (significance noted
at𝑃 < 0.05) and standard deviations between theHAQ,DAS-
28, and the SF-6D.
4. Discussion
Results obtained within this study highlight the evidence
of the significant improvement gained in the QOL caused
by this disabling condition in the initial treatment phases.
Various studies have used the HAQ to shed light on the
quality of life and physical disability endured by patients [18].
At baseline, patients reported a score ranging between 1.3 and
2.65. In a study by del Moral et al. [16], an HAQ score >1.5
was correlated with a significant number of working days
absenteeism (>50%) than those scoring <0.5. This implies
that costs are further increased by the loss of productivity
experienced by patients. During this study, indirect costs such
as loss of work were not included since a high percentage
of the subjects were housewives and thus it would be very
difficult to quantify the work carried out or the lack of it.
Following 3 months of treatment with TNF-𝛼 inhibitors,
scores ranged from 0.2 to 1.5, indicating a considerable
significant improvement (𝑃 < 0.05). Scores continued to
decrease furthermore during the last 3 months of the study
yet significance was not noted (𝑃 > 0.05).
Apart from the functional impairment assessed within
the HAQ, which hinders patients from their daily activities,
RA affects considerably the vitality, emotional wellbeing, and
mental health [19]. This has been confirmed by the low
mean scores reported in the study for all domains within
the SF-36 at phase 1. Despite multiple DMARD therapy
and concomitant glucocorticoids, patients experienced the
worst scores for the physical role and emotional role. All
domains improved significantly after 3 months of TNF-
𝛼 inhibitors (𝑃 < 0.05). In the latter half of the study,
significance was not noted since scores achieved were similar
to phase 2 apart from the emotional role which continued
to improve (𝑃 > 0.05). This is in concordance with the
findings from the HAQ which suggests that a “plateau” is
reached after 3 months of biological intervention. Such an
observation highlights the need for long-term studies, in
order to assess whether improvement gained is sustained and
to what extent. Findings from this study are in accordance
with results obtained from the generic SF-36 questionnaire
in a study conducted on a Spanish population [20]. Findings
from both HRQOL questionnaires used indicate the clinical
effectiveness of TNF-𝛼 antagonists in achieving a betterQOL,
as documented in various studies [20, 21].
The DAS-28 score used a clinical marker to monitor the
disease activity after intervention with TNF-𝛼 inhibitors. At
phase 1, 85% of subjects were experiencing a high disease
activity (>5.1) as devised by the EULAR criteria. Baseline
DAS-28 results further support the resulting disability and
compromised quality of life reported in the HRQOL ques-
tionnaires. Following 6 months of biological intervention,
prevalence of DAS-28 <3.2 was 31% (𝑛 = 4) which is
compatible with low disease activity. All patients (𝑛 = 13)
experienced significant reduction in disease activity (>1.2) as
defined by theACR/EULAR criteria. ACR/EULAR remission
(<2.6) was met by 15.4% (𝑛 = 2) of subjects. Abalos Medina
[20] reported a higher prevalence of ACR/EULAR remission,
yet this must be interpreted in the light of the limited number
of participants and length of the current study.
Recent therapeutic strategies in RA aim to slow down
disease progression and reduce functional impairment [22].
TNF-𝛼 antagonists are the forerunners in achieving such a
therapeutic goal as they have been proven to suppress disease
6 International Journal of Inflammation
Table 3: Resulting ICERs in terms of improvement in the HAQ.
Patients
Cost differences
between Treatment A
and B
Difference in HAQ
score between
Treatment A and B
ICER per unit of
improvement in HAQ
over 6 months
ICER per 10%
improvement in the
HAQ over 6 months
Patient 1 C6,451 0.85 C7,589 C2,277
Patient 2 C5,218 0.65 C8,028 C2,408
Patient 3 C5,444 2.15 C2,532 C759.6
Patient 4 C6,489 1.00 C6,489 C1,947
Patient 5 C5,302 0.90 C5,891 C1,767
Patient 6 C6,536 1.05 C6,225 C1,868
Patient 7 C6,476 1.15 C5,631 C1,689
Patient 8 C4,891 2.30 C2,127 C638.1
Patient 9 C5,705 1.30 C4,388 C1,316
Patient 10 C6,508 0.25 C26,030 C7,809
Patient 11 C5,649 1.50 C3,766 C1,130
Patient 12 C6,325 1.10 C5,750 C1,725
Patient 13 C1,802 1.50 C1,201 C360
Average C5,600 1.20 C6,588 C1,977
The ICERs per unit improvement and per 10% improvement in the HAQ following 6 months of TNF-𝛼 inhibitor therapy.
Table 4: Resulting ICERs in terms of improvement by the DAS-28.
Patients
Cost differences
between Treatment A
and B
Difference in DAS-28
score between
Treatment A and B
ICER per unit of
improvement in the
DAS-28 over 6 months
ICER per 10%
improvement in the
DAS-28 over 6 months
Patient 1 C6,451 3.72 C1,734 C1,630
Patient 2 C5,218 3.88 C1,345 C1,264
Patient 3 C5,444 3 C1,815 C1,706
Patient 4 C6,489 3.46 C1,875 C1,763
Patient 5 C5,302 1.79 C2,962 C2,784
Patient 6 C6,536 2.51 C2,604 C2,448
Patient 7 C6,476 3.25 C1,993 C1,873
Patient 8 C4,891 2.88 C1,698 C1,596
Patient 9 C5,705 2.16 C2,641 C2,483
Patient 10 C6,508 1.49 C4,368 C4,106
Patient 11 C5,649 1.89 C2,989 C2,810
Patient 12 C6,325 3.27 C1,934 C1,818
Patient 13 C1,802 2.01 C897 C843
Average C5,600 2.71 C2,220 C2,087
The ICERs per unit improvement and per 10% improvement in the DAS-28 following 6 months of TNF-𝛼 inhibitor therapy.
activity [1]. Since the procurement of TNF-𝛼 antagonists
is associated with incredibly high costs when compared
with conventional DMARD therapy, economic evaluations
are essential as benefit from biological treatment is evident,
but financial constraints limit its availability [23]. The HAQ
was chosen to assess the improvement achieved through
biological intervention, since a close correlation was reported
between HAQ and health care costs [24–26]. A unit of
improvement in the HAQ (any 1 unit difference between
0 and 3) was chosen as a health outcome benefit in order
to assess the ICER. The resulting ICERs per unit of HAQ
varied between C1,201 and C26,030 with a mean of C6,588.
Discrepancy between costs of treatment was offset by hip
replacement surgery for patient 13 which resulted in a more
favourable ICER. Such result is enlightening as it demon-
strates that TNF-𝛼 antagonist therapy is more likely to be cost
effective in patientswith severe functional disability, whomay
ultimately require surgical interventions.The least favourable
ICER was achieved by patient 10 who experienced the least
improvement in the HAQ (gain of 0.25). In such a scenario,
it is evident that the disease is resistant despite biological
treatment and alternative treatments should be initiated in
order to gain a better control of the disease and consequently
QOL. Kobelt et al. [27] described a similar situation where
International Journal of Inflammation 7
Table 5: Resulting ICERs in terms of improvement in the SF-6D.
Patient number
Cost differences
between Treatment A
and B
Difference in SF-6D
between Treatment A
and B
ICER per unit of
improvement in the
SF-6D
ICER per 10%
improvement in the
SF-6D
Patient 1 C6,451 0.35 C18,431 C1,843
Patient 2 C5,218 0.36 C14,494 C1,449
Patient 3 C5,444 0.22 C24,745 C2,475
Patient 4 C6,489 0.19 C34,152 C3,415
Patient 5 C5,302 0.18 C29,456 C2,946
Patient 6 C6,536 0.31 C21,084 C2,108
Patient 7 C6,476 0.18 C35,978 C3,598
Patient 8 C4,891 0.19 C25,742 C2,574
Patient 9 C5,705 0.19 C30,026 C3,003
Patient 10 C6,508 0.24 C27,117 C2,712
Patient 11 C5,649 0.37 C15,268 C1,527
Patient 12 C6,325 0.32 C19,766 C1,977
Patient 13 C1,802 0.37 C4,870 C487
Average C5,600 0.27 C23,164 C2,316
The ICERs per unit improvement and per 10% improvement in the SF-6D following 6 months of TNF-𝛼 inhibitor therapy.
Table 6: Statistical analysis between the choice of health outcome
used to express ICERs.
Health benefit outcome Mean (C) P value SD
HAQ 1976.469 1860.4
DAS-28 2086.469 0.789 837.3
SF-6D 2316.376 869.3
The level of significance (significance noted at 𝑃 < 0.05) and standard
deviations between the HAQ, DAS-28, and the SF-6D.
direct costs with a score >2.6 was approximately twice the
direct costs for patients achieving a score less than 0.6. This
highlights the need for effective treatment in order to achieve
maximal improvement in QOL and hence diminish the costs
incurred.
The DAS-28 is useful in indicating the suppression of
disease activity with biological intervention [13]. Such mea-
sure of health benefit was chosen as it is free of any bias
from both the researcher and the patient. Subjects achieved
an average significant reduction of 2.71 (>1.2) following 6
months of treatment. The highest ICER in terms of DAS-
28 was again reported by patient 10 which resulted due to a
minor improvement reported in the DAS-28. The resulting
ICERs ranged from C 897 to C4,368 with the lowest ICER
reported by patient 13.
The ICER per unit of improvement in the SF-6D gave
an average of C23,164 which is extremely higher than the
ICERs per unit of improvement in the HAQ and DAS-28.
Yet such a high cost resulted since it accounts for a transition
between death and a perfect quality of life. All ICER results
were expressed in terms of the same scoring scheme to be able
to compare results. For every 10% improvement in the SF-
6D, a cost of C2,316 was incurred after 6 months of TNF-𝛼
antagonist intervention. Statistical significance was not noted
(𝑃 > 0.05) between results obtained per 10% improvement
in the respective health outcome. This could be either due to
the limited number of observations (𝑛 = 13) or due to the
large variation in costs between the 13 observations of each
method as shown in the large standard deviations (Table 6).
Similar studies should be undertaken to be able to calculate
the cost effectiveness of such agents in terms of QALY so as to
provide to the health payer, with comparative data of the cost
effectiveness of this clinically effective treatment. Biologic
registers are of uttermost importance for such evaluations as
they can provide long-term data on TNF-𝛼 antagonists and
facilitate the path to model building for the calculation of
QALY [28].This data, which is currently unavailable inMalta,
could shed a more decisive light on the timely intervention
of TNF-𝛼 antagonists which could ultimately result in a
clinically effective, yet cost-effective treatment.
5. Conclusion
The economic burden of the biological agents and the
use of TNF-𝛼 antagonists in rheumatology is many times
questioned by policy makers and financial settings within a
national health service scheme. An improvement in quality
of life is achieved within 6 months of therapy, as shown in
this short-term study, and if this is sustained, the magnitude
of the pharmacoeconomic impact increases substantially.
This initial data could be useful to transmit the message to
policy makers that for each individual patient, the potential
of improving the quality of life and the pharmacoeconomic
benefit is evident. Long-term benefit of biological treatment
can hence be evaluated through further assessments.
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